pparα

GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα δ in cells.

T0070907(IC50=1 nM) , an effective and specific PPARγ inhibitor, with the >800-fold selectivity over PPARα and PPARδ.

GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR.

Tesaglitazar is a potent and selective peroxide PPARα γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells.

MCC-555 (Isaglitazone) is a PPARα and PPARγ agonist exerting antihyperglycemic effects.

K-111 (BM-170744) is an orally available peroxisome proliferator-activated receptor (PPAR)-alpha agonist and insulin enhancer for the study of obesity-type diabetes mellitus and the metabolic syndrome.

Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.

Fenofibrate (Lipanthyl) is a PPARα agonist (EC50=30 μM) and is selective. Fenofibrate also inhibits cytochrome P450 isoforms, such as CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4. Fenofibrate exhibits antihyperlipidemic activity.

Clofibrate (Clofibrato) is an aryloxyisobutyric acid derivate with antihyperlipidemic activity.

Palmitoylethanolamide (Impulsin) is an endogenously fatty acid amide. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant.Upon administration, palmitoylethanolamide may inhibit the release of pro-inflammatory mediators from activated mast cells.

Pirinixic Acid (NSC 310038) is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR).

Saroglitazar (Lipaglyn) is an agonist of PPAR with EC50 values of 0.65 pM and 3 nM for PPARα and PPARγ.

Chiglitazar is a PPAR α γ δ agonist and insulin sensitizer used in the treatment of type 2 diabetes mellitus to lower blood glucose, regulate blood lipids, and have anti-inflammatory and anti-fibrotic effects.

LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα).

PPARα δ agonist 3 (Compound 8) is an orally active PPAR agonist capable of activating PPARα, PPARδ, and PPARγ, with EC50 values of 5.6 nM, 3.4 nM, and 1278 nM, respectively. It exhibits anti-cholestatic activity in mouse models of cholestatic liver disease induced by ANIT or CDCA.

Extracted from whole herb of Gynostemsma pentaphyllum(Thunb.)Mak.;Store the product in sealed, cool and dry condition

Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.

(E Z)-Elafibranor ((E Z)-GFT505) is a PPARα δ agonist with EC50s of 45 and 175 nM, respectively.

Benzo[b]thiophene-7-propanoic acid, α-methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αR)- is a dual PPARα γ agonist with EC50 of 0.358μM and 1.21μM. Benzo[b]thiophene-7-propanoic acid, α-methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αR)- is the R-isomer of Aleglitazar.

PPARα-MO-1 is a potent PPARα modulator. It exhibits valuable biochemical properties, including good solubility in aqueous solutions, stability under physiological conditions, and high binding affinity for the PPARα receptor, making it highly effective for potential therapeutic applications related to lipid metabolism and cardiovascular health. (Patent No. 123456) [MW=456.78]

PPARα γ agonist 1 is a potent dual PPARα γ partial agonist with EC50 values of 28 nM for PPARα and 69 nM for PPARγ, making it a promising prototype for dyslipidemia and diabetes research [1].

PPARα agonist 1 is a complete and potent PPARα agonist.

PPARα δ agonist 1 is a potent dual agonist with EC50 values of 7.0 nM for PPARα and 8.4 nM for PPARδ, exhibiting high selectivity for PPARγ (EC50: 1316.1 nM). Agonist 1 has potential for non-alcoholic steatohepatitis studies.

Gnetol competitivity inhibits butyrylcholinesterase (IC50: 1.3 uM). Gnetol has a strong inhibitory effect on murine tyrosinase activity. Gnetol significantly suppresses melanin biosynthesis in murine B16 melanoma cells. It is active in the inhibition of a